tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PCVX Stock Latest News

Needham ups Vaxcyte target, adds to Conviction List
The FlyNeedham ups Vaxcyte target, adds to Conviction List
9d ago
PCVX
PHAT
Buy Rating on Vaxcyte: De-Risked VAX-31 Clinical Profile, Strong Cash Position, and Attractive Entry Ahead of 2026 Phase 3 Catalyst
PremiumRatings
Buy Rating on Vaxcyte: De-Risked VAX-31 Clinical Profile, Strong Cash Position, and Attractive Entry Ahead of 2026 Phase 3 Catalyst
9d ago
PCVX
Mizuho positive on Vaxcyte after HHS maintains PCV schedule for children
PremiumThe Fly
Mizuho positive on Vaxcyte after HHS maintains PCV schedule for children
10d ago
PCVX
Vaxcyte Enhances Executive Severance to Align With Market
PremiumCompany Announcements
Vaxcyte Enhances Executive Severance to Align With Market
27d ago
8K
PCVX
Promising Potential of Vaxcyte’s VAX-31 Vaccine Drives Buy Rating
PremiumRatings
Promising Potential of Vaxcyte’s VAX-31 Vaccine Drives Buy Rating
1M ago
PCVX
Vaxcyte’s Strategic Phase 3 Trial Initiation and Its Market Implications
PremiumRatingsVaxcyte’s Strategic Phase 3 Trial Initiation and Its Market Implications
1M ago
PCVX
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31
Premium
The Fly
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31
1M ago
PCVX
Vaxcyte, Inc. Reports Q3 2025 Financial Results
Premium
Company Announcements
Vaxcyte, Inc. Reports Q3 2025 Financial Results
2M ago
PCVX
Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte
PremiumRatings
Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte
2M ago
PCVX
Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)
PremiumThe Fly
Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)
2M ago
PCVX
Vaxcyte’s VAX-31 Study: A Potential Game-Changer in Infant Vaccination
PremiumCompany Announcements
Vaxcyte’s VAX-31 Study: A Potential Game-Changer in Infant Vaccination
3M ago
PCVX
Vaxcyte price target lowered to $85 from $160 at BTIG
PremiumThe Fly
Vaxcyte price target lowered to $85 from $160 at BTIG
3M ago
PCVX
Vaxcyte Signs 15-Year Agreement with Patheon
PremiumCompany AnnouncementsVaxcyte Signs 15-Year Agreement with Patheon
4M ago
8K
PCVX
Vaxcyte to establish fill-finish manufacturing in North Carolina
Premium
The Fly
Vaxcyte to establish fill-finish manufacturing in North Carolina
4M ago
TMO
PCVX
Vaxcyte initiated with a Neutral at Goldman Sachs
Premium
The Fly
Vaxcyte initiated with a Neutral at Goldman Sachs
4M ago
PCVX
Vaxcyte advances VAX-31 infant Phase 2 study
PremiumThe Fly
Vaxcyte advances VAX-31 infant Phase 2 study
4M ago
PCVX
Vaxcyte Reports Progress in Vaccine Development
PremiumCompany Announcements
Vaxcyte Reports Progress in Vaccine Development
5M ago
PCVX
Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating
PremiumRatings
Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating
5M ago
PCVX
Vaxcyte price target lowered to $50 from $85 at TD Cowen
PremiumThe Fly
Vaxcyte price target lowered to $50 from $85 at TD Cowen
5M ago
PCVX
Vaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating
PremiumRatingsVaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating
5M ago
PCVX
Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating
Premium
Ratings
Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating
5M ago
PCVX
Vaxcyte reports Q2 EPS ($1.22), consensus ($1.16)
Premium
The Fly
Vaxcyte reports Q2 EPS ($1.22), consensus ($1.16)
5M ago
PCVX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >